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A bst r a c t 
B ac kg ro un d : Chorioni c villus sampling (CVS) and amniocentesis are two invasive methods of diagnostic 
approaches for prenatal diagnosis. The indication, adverse effects and final outcome of these two methods are 
different. The goal of this study was to compare indication, complications and outcomes of CVS and 
amniocentesis in pregnant women underwent prenatal screening program. 
M et hods: Medica l records of 1464 women who underwent CVS, or amniocentesis were reviewed in two 
tertiary hospitals (imam and women hospitals, affiliated hospitals of Tehran University of Medical Sciences). 
Resul t s : Fo r 1073 patients amniocentesis was performed while for 391 cases CVS was one. Mean maternal 
age, gestational age, and age at birth of the neonates were significantly lower in CVS group than the other 
group. Mean needle time was significantly higher in CVS group. Mean needle time was significantly higher in 
CVS Group (1.3 vs. 1.5, P < 0.001). The most finding of CVS result was minor Thalassemia while trisomy 21 
was the most finding in amniocentesis group. Rupture of membranes was the most side effects in 
amniocentesis group and intrauterine fetal death was the most complication in CVS group. 
Conclusions: Indication, results and complications of CVS and amniocentesis are different. 
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I n trod u cti on  
Chorionic villus sampling (CVS) is an ambulatory 
procedure conducted prior to 12 weeks of gestation for 
prenatal diagnosis (1). CVS is performed in 
pregnancies with advanced maternal age, first trimester 
screening for Down’s syndrome, and in high risk 
groups according to US preventive services task force 
and the society of obstetricians and gynecologists 
Canada, in conjunction with the Canadian College of 
Medical Geneticists (2). It is a safe procedure with 
reported fetal loss between 0.5% and 1.5% (3). 
Miscarriage, infection, rhesus sensitization are 
complications of CVS.  
Amniocentesis is another invasive diagnostic 
method for prenatal diagnosis which is invasive and 
provides information regarding chromosomal 
abnormalities (4). Although, it is an invasive method, 
fetal loss rate reported in 0.06% and 1% of performed 
procedures (5,6). Procedure-related complications after 
amniocentesis include miscarriage, infection, club foot, 
and puncture of the placenta. Different factors such as 
trans-placental needle insertion, angle of puncture, 
numerous punctures, fetal abnormalities and 
experience of the operator are related with fetal loss 
following amniocentesis (7-10). Previous studies 
showed that different diameters of the needle are 
important in the occurrence of adverse effects (5,8,11). 
We designed this study to find out indications, 
complications and outcomes of CVS and amniocentesis 
in pregnant women underwent prenatal screening 
programs. 
Materi al s  an d  Meth od s  
In this retrospective study, medical records of 1464 
women who underwent CVS, or amniocentesis were 
reviewed in two tertiary hospitals (Imam and Women 
hospitals, affiliated hospitals of Tehran University of 
Medical Sciences). The procedures were conducted 
during 10 years, using 22 gauze needles.  
A structured questionnaire applied to collect 
information regarding (age, gravidity, live birth, 
gestational age, placenta location, indication of 
procedure, alpha-fetoprotein level, procedure 
complications, final outcome (abortion, live birth, 
intrauterine fetal death [IUFD]), number of needling, 
human chorionic gonadotropin level, and age at birth. 
Statistical analyses performed with SPSS (version 
18; SPSS Inc., Chicago, IL, USA). Results are 
presented as mean ± standard deviations, and 
frequencies. The χ² test with Fisher’s exact test was 
applied for comparing categorical variables and 
ANOVA test used to compare continuous variables. 
P < 0.050 was considered statistically significant.  
Res u l ts  
Medical records of 1464 patients reviewed. For 1073 
patients amniocentesis was performed while for 391 
cases CVS was one. Table 1 shows basic 
characteristics of patients in both groups. 
Mean needle time was significantly higher in CVS 
group (Table 2). 
The mean number of needle time according to 
placenta location was not significantly different in both 
groups (Table 3). 
The most finding of CVS result was minor 
 
thalassemia while trisomy 21 was the most finding in 
amniocentesis group (Table 4). 
Rupture of membranes was the most side effects in 
amniocentesis group, and IUFD was the most 
complication in CVS group (Table 5). 
Di s cu s s i on 
The result of the current study showed that mean 
maternal age, gestational age, and age at birth of the 
neonates were significantly lower in CVS group than 
the other group (Table 6). 
The results also showed that in both groups, the 
placenta was located mainly at the anterior position and 
mean number of needle time in two groups according 
to the location of the placenta was not significantly 
different. In CVS group, the previous history of the 
problem was the most reason for doing the procedure 
while in amniocentesis group the main reason was 
abnormal biomarkers. 
Daniilidis et al. reviewed medical records of patients 
attended to their clinic for amniocentesis during 4 years 
(12). In their study, amniocentesis result was normal in 
93% and Down syndrome was detected in 4%. 
Tabl e 1 .  Basic characteristics of patients in both groups 
Cha ract eri st i cs  A mni oce nt esi s  CVS  P  val ue  
Maternal age 33.6 ± 6.1 28 ± 6.6 < 0.001 
Gravidity 2.5 ± 1.4 2.2 ± 1.4 < 0.001 
Live birth 1 ± 0.9 0.7 ± 1 < 0.001 
Gestational age 18.6 ± 4.3 12.5 ± 2.4 < 0.001 
Age at birth 36.5 ± 5.4 33.1 ± 9.9 < 0.001 
Placenta location 
Anterior 540 192 
0.007 
Posterior 380 163 
Fundal 117 20 
Previa 13 5 
Lateral 23 11 
CVS: Chorionic villus sampling 
Tabl e 2 .  Procedure related factors in both groups 
F act or s  A mni oce nt esi s  CVS  P  val ue  
AFP 1 ± 0.8 0.9 ± 0.6 0.500 
hCG 2 ± 2.3 2 ± 1 0.900 
Needle time 1.3 ± 0.6 1.5 ± 0.7 < 0.001 
Indication of procedure 
Maternal age 491 53 < 0.001 
According to sonography findings 73 16 0.100 
According to biomarkers 777 25 < 0.001 
Maternal request 55 4 < 0.001 
Previous history of problem in children 158 342 
CVS: Chorionic villus sampling; AFP: Alpha-fetoprotein, hCG: Human chorionic gonadotropin 
Tabl e 3 .  Mean number of needle time in two groups according to location of the placenta 
Gro u ps  Ant eri or  P ost eri o r  F un dal  P revi a  Lat er al  P  val ue  
Amniocentesis 1.3 ± 0.6 1.2 ± 0.5 1.2 ± 0.6 1.1 ± 0.3 1.5 ± 0.7 0.080 
CVS 1.5 ± 0.7 1.5 ± 0.7 1.7 ± 0.9 1.2 ± 0.4 1.1 ± 0.4 0.200 
CVS: Chorionic villus sampling 
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Tabl e 4 .  Results of two procedures 
Resul t s  A mni oce nt esi s ( %)  CVS  ( %)  P-value 
Normal 950 (88.5) 169 (43.2) 
< 0.001 
Trisomy 21 57 (5.3) 12 (3) 
Trisomy 18 15 (1.3) 3 (0.7) 
NTD 4 (0.3) 0 
Major thalassemia 1 (0.09) 69 (17.6) 
Minor thalassemia 1 (0.09) 117 (29.9) 
Hemophilia 2 (0.18) 7 (1.7) 
Others 43 (4) 14 (3.4) 
NTD: Neural tube deficit; CVS: Chorionic villus sampling 
Tabl e 5 .  Side-effects of the procedures 
S i de- ef f ect s  A mni oce nt esi s  CVS  P - val u e
Abortion 1 2 
0.040 
Bleeding 0 2 
ROM 3 1 
IUFD 2 3 
Chorioamnionitis 2 0 
ROM: Rupture of membranes; CVS: Chorionic villus sampling; IUFD: Intrauterine fetal death 
Tabl e 6 .  Final outcome 
Gro u ps  Li ve bi rt h ( %)  Abortion or termination (%) IUFD (%) P-value 
Amniocentesis 965 (89.9) 79 (7.3) 29 (2.7) 
< 0.001 CVS 316 (80.8) 66 (16.8) 9 (2.3) 
CVS: Chorionic villus sampling; IUFD: Intrauterine fetal death 
The outcome of pregnancy was live births in 89%, 
stillbirths in 3% (2/73), miscarriages in 1% and 
terminations in 7%. In our study, down syndrome 
detected in 5% of cases who underwent amniocentesis 
and abortion or termination done in 7%. 
Brambati et al. performed CVS on 1,844 women at 
weeks 13-20 of gestational age in whom the indication 
of the procedure was chromosomal anomalies in 
85% (13). 
Tchirikov et al. evaluated 311 patients who 
underwent amniocentesis. They reported that the 
indication for amniocentesis was mostly advanced 
maternal age, followed by positive family anamnesis 
(4). The most karyotype in their study was trisomy 21, 
followed by trisomy 18 which is consistent with our 
finding. They reported no procedure complication in 
their cases while we detected 8 complications related to 
the amniocentesis. The mean rate of complications of 
amniocentesis such as miscarriage, amniotic fluid loss, 
bleeding, pyrexia, etc.) reported between 1% and 2% in 
previous studies (5,6,14,15). 
In a single center 16 years experience, Odibo et al. 
reported a total fetal loss in 0.4% of patients underwent 
amniocentesis and 0.26% in the group without this 
procedure (10). In CVS group, abortion occurred in 2 
(0.5%) which is lower than the rate reported by 
Choudry et al. (1.5%) (3). 
Since-mid 1960, when chromosome analysis after 
amniocentesis introduced by Steele and Breg (16), 
screening for chrosomal abnormalities before birth 
becomes possible. Amniocentesis is an invasive 
method which is the most common prenatal diagnostic
procedure. The aim of amniocentesis is obtaining fetal 
cells derived from skin, mucous membranes, amnion, 
and umbilical cord for karyotyping or DNA 
analysis (12). 
It is usually performed between 15 and 20 weeks of 
gestational age and performing the procedure before 14 
weeks of gestational age is related to the higher rate of 
miscarriage (12). Literature showed that procedure 
related complications could be controlled by the size of 
the needle used for the procedure (5,11,17). 
In most centers, it is performed by means of a 22-
gauze spinal needle transabdominally under ultrasound 
guidance. The needle size which was used for both 
procedures in our cases was 22 gauge. 
In a previous study, Tchirikov et al. used 29 gauge 
needle for amniocentesis for 316 patients and reported 
no procedure-related fetal loss. No other complications 
were observed (4). However, the 29 gauge needle has 
its limitations such as higher risk of bending and it 
needs more attention for obese cases (4). The cost of 
the needle in our center is 1$ but the cost is near 25$ in 
other countries. 
CVS is a diagnostic test for inherited disorders 
which involves removing some chorionic villi cells 
from the placenta before 14th weeks of gestational age 
(3). The most indication for CVS is an increased risk of 
fetal aneuploidies due to advanced maternal age, 
family history or abnormal screening tests (3). CVS is 
related with fetal limb reduction defects, pre-
eclampsia, focal placental hemorrhage and 
inflammation (18). We found none of these 
complications in this study. 
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Con cl u s i on 
Indication, results and complications of CVS and 
amniocentesis are different. So, the proper method 
should be considered for a specific patient. 
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